EOD Primary Tumor
Notes
**Note 1:** **The following histologies can be localized (code 100), systemic (700) or unknown (999)**
* 9740: Mast cell sarcoma (MCS)
* 9749: Erdheim-Chester disease (ECD) (2021+ only)
* 9755: Histiocytic sarcoma
* 9756: Langerhans cell sarcoma (LCS)
* 9757: Interdigitating dendritic cell sarcoma (IDCS)
* 9758: Follicular dendritic cell sarcoma (FDCS)
* 9759: Fibroblastic reticular cell tumor
* 9766: Lymphomatoid granulomatosis, grade 3 (2021+ only)
* 9930: Myeloid sarcoma
* 9971: Polymorphic PTLD (2018-2020, 2025+)
* *Note:* 9971 is /1 and non-reportable (except for C700-C729, C751-C753) for 2021-2024, moved back to /3 for 1/1/2025+
**Note 2:** **Lymph node involvement**
* For histologies listed in **Note 1**, it is possible to have lymph node involvement; however, at this time, lymph node involvement for these histologies is not collected.
**Note 3:** **The following histologies are systemic (code 700):**
* 9591 Splenic B-cell lymphoma/leukemia, unclassifiable (except C441, C690, C695-C696)
* 9724: Systemic EBV-positive T-cell lymphoma of childhood (SEBVTCL)
* 9727: Blastic plasmacytoid dendritic cell neoplasm (BPDC)
* 9741: Systemic mastocytosis with an associated hematological neoplasm (SM-AHN)
* 9742: Mast cell leukemia (MCL)
* 9750: ALK-positive histiocytosis
* 9751: Langerhans cell histiocytosis (LCH), disseminated
* 9762: Heavy chain diseases, NOS (HCD)
* 9800 Leukemia, NOS
* 9801: Acute undifferentiated leukemia
* 9805: Acute leukemia of ambiguous lineage with other defined genetic alterations
* 9806: Mixed-phenotype acute leukemia (MPAL) with *BCR::ABL1* fusion
* 9807: Mixed-phenotype acute leukemia (MPAL) with *KMT2A-rearranged*
* 9808: Mixed -phenotype acute leukemia, B/myeloid, NOS
* 9809: Mixed-phenotype acute leukemia (MPAL), T/myeloid, NOS
* 9811: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL], NOS
* 9812: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *BCR::ABL1 fusion*
* 9813: B lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *KMT2A rearrangement*
* 9814: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *ETV6::RUNX1 fusion*
* 9815: B-lymphoblastic leukemia/lymphoma with high hyperdiploidy (B-ALL/LBL with high hyperdiploidy)
* 9816: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with hypodiploidy (Hypodiploid B-ALL/LBL)
* 9817: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *IGH::IL3 fusion*
* 9818: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *TCF3::PBX1*
* 9819: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *BCR::ABL1 like features* (BCR::ABL1-like B-ALL/LBL) (2021+ only)
* 9820: Lymphoid leukemia, NOS
* 9831: T-large granular lymphocytic leukemia (T-LGLL)
* 9832: Prolymphocytic leukemia (PPL), NOS
* 9833: Prolymphocytic leukemia, B-cell type (BLL)
* 9834: T-cell prolymphocytic leukemia (T-PLL)
* 9837: T-lymphoblastic leukemia/lymphoma (T-ALL/LBL)
* 9840: Acute erythroid leukemia (AEL)
* 9860: Myeloid leukemia, NOS
* 9861: Acute myeloid leukemia (AML), NOS
* 9863: Chronic myeloid leukemia (CML), NOS
* 9865: Acute myeloid leukemia with *DEK::NUP214 fusion*
* 9866: Acute promyelocytic leukemia with *PML::RARA* fusion (APL with *PML::RARA*)
* 9867: Acute myelomonocytic leukemia, NOS (AMML)
* 9869: Acute myeloid leukemia with *MECOM rearrangement*
* 9870: Acute basophilic leukemia
* 9871: Acute myeloid leukemia with *CBFB::MYH11 fusion*
* 9872: Acute myeloid leukemia, minimal differentiation
* 9873: Acute myeloid leukemia without maturation
* 9874: Acute myeloid leukemia with maturation
* 9875: Chronic myeloid leukemia (CML), *BCR::ABL1 positive*
* 9876: Myelodysplastic/myeloproliferative neoplasm with neutrophilia (MDS/MPN-N)
* 9877: Acute myeloid leukemia with mutated *NPM1* (2021+ only)
* 9878: Acute myeloid leukemia with *CEBPA mutation* (2021+ only)
* 9879: Acute myeloid leukemia with mutated *RUNX1* (2021+ only)
* 9891: Acute monocytic leukemia
* 9895: Myelodysplasia-related acute myeloid leukemia (AML-MR)
* 9896: Acute myeloid leukemia with *RUNX1::RUNX1T1*
* 9897: Acute myeloid leukemia with *KMT2a rearrangement*
* 9898: Myeloid leukemia associated with Down Syndrome (ML-DS)
* 9910: Acute megakaryoblastic leukemia (AMKL)
* 9911: Acute myeloid leukemia (megakaryoblastic) with *RBMI5::MRTFA*
* 9912: Acute myeloid leukemia with *BCR::ABL1 fusion* (2021+ only)
* 9920 Therapy-related myeloid neoplasms
* 9931: Acute panmyelosis with myelofibrosis (APMF)
* 9940: Hairy cell leukemia (HCL)
* 9945: Chronic myelomonocytic leukemia, NOS (CMML)
* 9946: Juvenile myelomonocytic leukemia (JMML)
* 9948: Aggressive NK-cell leukemia (ANKL)
* 9950: Polycythemia vera (PV)
* 9961: Primary myelofibrosis (PMF)
* 9962: Essential thrombocythemia (ET)
* 9963: Chronic neutrophilic leukemia (CNL)
* 9964: Chronic eosinophilic leukemia (CEL)
* 9965: Myeloid/lymphoid neoplasms with *PDGFRA* rearrangement
* 9966: Myeloid/lymphoid neoplasm with *PDGFRB* rearrangement
* 9967: Myeloid/lymphoid neoplasm with *FGFR1* rearrangement
* 9968: Myeloid/lymphoid neoplasm with *JAK2* rearrangement (2021+ only)
* 9975: Myelodysplastic/myeloproliferative neoplasm, NOS, unclassifiable (MPN/MDS-U)
* 9980: Myelodysplastic neoplasm with low blasts and single-lineage dysplasia (MDS-LB-SLD)
* 9982: Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia (MDS-RS-SLD)
* 9983: Myelodysplastic neoplasm with increased blasts (MDS-IB)
* 9985: Myelodysplastic neoplasm with low blasts, NOS (MDS-LB)
* 9986: Myelodysplastic neoplasm with low blasts and 5q deletion (MDS-5q)
* 9989: Myelodysplastic neoplasm, NOS
* 9991: Refractory neutropenia (2018-2020 only, see code 9980/3 for 2021+)
* 9992: Refractory thrombocytopenia (2018-2020 only, see code 9980/3 for 2021+)
* 9993: Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (2021+)
| Code |
Description |
SS2018 T |
| 100 |
Localized disease
(Single/solitary/unifocal/isolated)
See Notes 1 and 2 |
L |
| 700 |
Systemic disease
See Note 3 |
D |
| 999 |
Unknown; extension not stated
Primary tumor cannot be assessed
Not documented in medical record
Death Certificate Only |
U |
(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998
(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.
(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)
(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017
(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017
(6) Radich, J.P., Jaffe, E.S., Leonard, J.P., et al. **Leukemia**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017
